#United States #Los Angeles #Schall Law Firm #Fraud Investigation #uniQure N.V.

An Important Call to uniQure N.V. Investors

In the realm of investment, maintaining transparency and honesty between a company and its shareholders is critical. Recently, the Schall Law Firm publicly announced its investigation into uniQure N.V., a prominent player in the biotechnology sector. This inquiry raises significant concerns among investors, many of whom may have already experienced considerable losses.

Context of the Investigation

On November 3, 2025, an alarming press release from uniQure indicated that the company had received feedback from the FDA regarding the data derived from the Phase I/II studies of its treatment, AMT-130. This feedback suggests the FDA no longer believes this data can adequately support a Biologics License Application (BLA) submission — a critical step for any biotech firm aiming to bring a new drug to market. As a result of this revelation, uniQure's stock plummeted, shedding over 57% of its value within a matter of hours. This dramatic decline has significantly impacted investors, leading to concerns about their rights and financial securities.

Why This Matters

The Schall Law Firm specializes in securities class action lawsuits and has taken proactive steps to represent shareholder interests in cases like this. Investors who feel misled or who suffered a financial setback due to the company's disclosures are encouraged to participate in the investigation. The investigation revolves around potential violations of securities laws, particularly focusing on the accuracy of information disseminated by uniQure and the possible repercussions of their statements on stock performance.

How Investors Can Respond

If you are a shareholder of uniQure N.V. and have sustained losses as a result of this situation, it is vital to know that you have options. The Schall Law Firm is offering consultations to discuss your legal rights without any obligation. Reaching out to the firm allows affected investors to navigate the complexities of securities law effectively and identify potential paths toward recouping losses. Investors are encouraged to keep track of developments in this case, given the potential for significant legal and financial outcomes.

Take Action Today

The rapidly changing dynamics in biotech therapy bring with them uncertainties that can affect stocks and investor morale. As the investigation progresses, those who stand to lose without appropriate recourse may find solace in joining collective legal action. When engaging with legal firm representatives, investors should be prepared to share specific details of their investments and the impact they have experienced. The time to act is now, as waiting may limit their options and potential recovery.

Contact Information

For further details, investors can directly reach out to Brian Schall at the Schall Law Firm, located in Los Angeles. The firm can assist investors in recovering their financial losses, ensuring their rights are observed. Contact them via their website at www.schallfirm.com or by phone at 310-301-3335.

Conclusion

The investigation into uniQure N.V. represents a crucial opportunity for investors to seek justice and reparation for their losses. Engaging with experienced legal representatives can clarify uncertain issues surrounding potential securities fraud, thus bolstering the investment community's resilience. Stay informed, stay proactive, and ensure your rights as a shareholder are protected.